Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043678 · ClinicalTrials.gov registry record · Phase 3
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
A Phase 3 study of Prostatic Neoplasms, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 806
- Enrollment target
- 20
- Study locations
NCT02043678: Completed Phase 3 study of Prostatic Neoplasms, sponsored by Bayer.
NCT02043678 is a Phase 3 study of Prostatic Neoplasms that has completed, run by Bayer. The registered enrollment target is 806 participants, above the 502-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (61% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02043678, a Phase 3 study of Prostatic Neoplasms, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 806 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine.
Primary Outcome
SSE-FS was defined as time (months) from randomization to the earliest of onset date of skeletal symptoms treated with external beam radiotherapy (EBRT), onset date of pathological bone fracture, onset date of spinal cord compression, procedure date of tumor-related orthopedic surgery, or death from any cause. Participants who died without prior SSE and ≥ 13 weeks after the last SSE assessment are censored at the last SSE assessment date. Participants alive at the survival cut-off date are censo
Conditions Studied
Interventions
- DRUG Abiraterone
- DRUG Prednisone/Prednisolone
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
- DRUG Matching placebo (normal saline)
Study Locations (20)
Maryland
- - Baltimore
- - Rockville
- - Towson
Massachusetts
- - Boston
- - Burlington
Michigan
- - Detroit
- - Traverse City
Alaska
- - Anchorage
Arizona
- - Tucson
California
- - Oceanside
Colorado
- - Denver
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 806 participants |
| Start Date | 2014-03-30 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 3 |
What the finished NCT02043678 record still lists
NCT02043678 is an interventional study that assigns participants to a tested intervention. The registered 806 participants enrollment target is mid-sized for trials with a published cap, above the 502-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (61% higher).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Abiraterone is the first listed.
NCT02043678 names 20 study sites across 16 states, led by Maryland, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT02043678 about?
NCT02043678 is a clinical study titled "Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms". To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine.
What is the current status of trial NCT02043678?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 806 participants. The study started on 2014-03-30. Estimated completion is 2024-02-08.
What conditions does trial NCT02043678 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02043678?
The interventions under investigation include: Abiraterone (DRUG), Prednisone/Prednisolone (DRUG), Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG), Matching placebo (normal saline) (DRUG).
Who is sponsoring clinical trial NCT02043678?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02043678 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02043678's enrollment target sits among peer trials
806 19th of 65 higher than 47 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RECRUITING · Phase 3
-
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 3
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ACTIVE NOT RECRUITING · Phase 3
-
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI